Edition:
India

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

6.95USD
16 Feb 2018
Change (% chg)

$0.15 (+2.21%)
Prev Close
$6.80
Open
$6.85
Day's High
$6.95
Day's Low
$6.70
Volume
15,521
Avg. Vol
18,040
52-wk High
$11.73
52-wk Low
$5.60

Latest Key Developments (Source: Significant Developments)

Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS.  Full Article

Cidara reports qtrly ‍basic and diluted net loss per share $0.73​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::Cidara provides corporate update and reports third quarter 2017 financial results.Cidara Therapeutics Inc - qtrly ‍basic and diluted net loss per share $0.73​.Cidara Therapeutics Inc - qtrly ‍total operating expenses $12.2 million versus $12.3 million.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.  Full Article

Cidara Therapeutics prices public offering of 2.48 mln common shares at $10.10 per share
Friday, 7 Oct 2016 

Cidara Therapeutics Inc : Cidara Therapeutics announces pricing of public offering of common stock .Says public offering of 2.48 million common shares priced at $10.10per share.  Full Article

Cidara Therapeutics enters loan and security deal for $10 mln
Tuesday, 4 Oct 2016 

Cidara Therapeutics Inc :Entered into a loan and security agreement for $10.0 million -sec filing.  Full Article

Cidara Therapeutics posts Q2 loss per share $0.85
Friday, 12 Aug 2016 

Cidara Therapeutics Inc : Qtrly loss per share $0.85 .Q2 earnings per share view $-0.76 -- Thomson Reuters I/B/E/S.  Full Article

Cidara therapeutics says Matthew Onaitis appointed CFO
Tuesday, 5 Jul 2016 

Cidara Therapeutics Inc : Says Matthew W. Onaitis appointed CFO .Prior to joining Cidara, Onaitis was general counsel and secretary of Ignyta, Inc.  Full Article

Cidara files for mixed shelf of up to $150 mln - SEC filing
Friday, 20 May 2016 

Cidara Therapeutics Inc :Files for mixed shelf of up to $150 million - sec filing.  Full Article

Aisling Capital II reports 7.4 pct passive stake in Cidara Therapeutics
Wednesday, 18 May 2016 

Cidara Therapeutics Inc :Aisling Capital II, LP reports 7.4% passive stake in Cidara Therapeutics Inc as of December 31, 2015 - SEC Filing.  Full Article

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage: